These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
458 related articles for article (PubMed ID: 27012989)
1. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989 [TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients. Kitano Y; Yamashita YI; Nakao Y; Itoyama R; Yusa T; Umezaki N; Tsukamoto M; Yamao T; Miyata T; Nakagawa S; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H Ann Surg Oncol; 2020 Feb; 27(2):599-607. PubMed ID: 31407173 [TBL] [Abstract][Full Text] [Related]
3. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma. Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY Front Immunol; 2021; 12():705378. PubMed ID: 34526987 [TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications. Yu F; Gong L; Mo Z; Wang W; Wu M; Yang J; Zhang Q; Li L; Yao J; Dong J Biosci Trends; 2019 Mar; 13(1):58-69. PubMed ID: 30773525 [TBL] [Abstract][Full Text] [Related]
5. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma. Dong Z; Liao B; Shen W; Sui C; Yang J Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753 [TBL] [Abstract][Full Text] [Related]
6. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells. Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828 [TBL] [Abstract][Full Text] [Related]
8. Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma. Lozzi I; Arnold A; Barone M; Johnson JC; Sinn BV; Eschrich J; Gebert P; Wang R; Hu M; Feldbrügge L; Schirmeier A; Reutzel-Selke A; Malinka T; Krenzien F; Schöning W; Modest DP; Pratschke J; Sauer IM; Felsenstein M Oncoimmunology; 2024; 13(1):2406052. PubMed ID: 39359389 [TBL] [Abstract][Full Text] [Related]
9. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168 [TBL] [Abstract][Full Text] [Related]
12. M Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762 [TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. de Vicente JC; Rodríguez-Santamarta T; Rodrigo JP; Blanco-Lorenzo V; Allonca E; García-Pedrero JM Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):546-554. PubMed ID: 30487133 [TBL] [Abstract][Full Text] [Related]
14. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043 [TBL] [Abstract][Full Text] [Related]
15. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1. Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721 [TBL] [Abstract][Full Text] [Related]
17. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. Kamamoto D; Ohara K; Kitamura Y; Yoshida K; Kawakami Y; Sasaki H J Neurooncol; 2018 Sep; 139(2):251-259. PubMed ID: 29675794 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717 [TBL] [Abstract][Full Text] [Related]
19. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1. Liu Z; Li S; Zeng J; Zhou X; Li H; Liu X; Li F; Jiang B; Zhao M; Ma T Life Sci; 2020 Sep; 257():118068. PubMed ID: 32653521 [TBL] [Abstract][Full Text] [Related]
20. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases. Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]